J Wrist Surg 2020; 09(02): 124-128
DOI: 10.1055/s-0039-3400465
Scientific Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Acute Complications in Total Wrist Arthroplasty: A National Surgical Quality Improvement Program Review

Michael D. Eckhoff
1   Department of Orthopaedics, William Beaumont Army Medical Center, El Paso, Texas
,
Julia M. Bader
2   Department of Clinical Investigation, William Beaumont Army Medical Center, El Paso, Texas
,
Leon J. Nesti
3   Clinical and Experimental Orthopaedics, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland
,
John C. Dunn
1   Department of Orthopaedics, William Beaumont Army Medical Center, El Paso, Texas
› Author Affiliations

Funding None.
Further Information

Publication History

12 July 2019

10 October 2019

Publication Date:
26 November 2019 (online)

Preview

Abstract

Background The study sought to assess the patient-based variables, surgical risk factors, and postoperative conditions associated with readmission after total wrist arthroplasty (TWA).

Materials and Methods All patients undergoing TWA were identified from the National Surgical Quality Improvement Program dataset from 2005 to 2016. Patient demographics, medical comorbidities, surgical characteristics, and outcomes were examined to isolate predictors for readmission within 30 days postoperatively.

Results A total of 57 patients were identified to have undergone TWA. The average patients were 62.3 (13.8) years old, female (57.7%), and most were treated in the outpatient setting (67.3%). Comorbid conditions included smoking (17.3%), diabetes (15.4%), and chronic steroid therapy (15.4%). No complications were identified in the 30-day postoperative period. There was a trend for increasing utilization of TWA over the years included.

Conclusion TWA is a safe procedure with low complication rates in the acute postoperative period. Increasing utilization is likely a result of improved outcomes and cost-effectiveness of TWA.

Level of Evidence This is a Level II, prognostic study.

Note

This study was approved by our Institutional Review Board. All procedures followed as part of this study were in accordance with ethical standards of the Institutional Review Board and with the Helsinki Declaration of 1975, revised in 2000. This study was exempt from obtaining informed consent by the Institutional Review Board at our institution.